Breast Cancer and Breast Health

Episodes 1-11 of 11

• 

  RestartResume

  Expert Viewpoint: Optimizing Breast Cancer Treatment  

  RestartResume

  Expert Viewpoint: Optimizing Breast Cancer Treatment  

  MinuteCE®

  Expert Viewpoint: Optimizing Breast Cancer Treatment  

  1.50 program credits

  • 

    

    William J. Gradishar, MD

  • 

    

    Erica L. Mayer, MD, MPH

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 program credits

• 

  RestartResume

  Management of HR+, HER2- High-Risk EBC 

  RestartResume

  Management of HR+, HER2- High-Risk EBC 

  MinuteCE®

  Management of HR+, HER2- High-Risk EBC 

  1.50 program credits

  • 

    

    Erica L. Mayer, MD, MPH

  1.50 program credits

• 

  RestartResume

  Management of HER2-Low MBC Following First-Line Disease Progression

  RestartResume

  Management of HER2-Low MBC Following First-Line Disease Progression

  MinuteCE®

  Management of HER2-Low MBC Following First-Line Disease Progression

  1.50 program credits

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 program credits

• 

  MinuteCE®

  Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer

  1.50 credits 10 episodes

  • 

    

    William J. Gradishar, MD

  • 

    

    Erica L. Mayer, MD, MPH

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 credits 10 episodes

• 

  RestartResume

  Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC  

  RestartResume

  Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC  

  MinuteCE®

  Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC  

  1.50 program credits

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 program credits

• 

  RestartResume

  Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors

  RestartResume

  Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors

  MinuteCE®

  Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors

  1.50 program credits

  • 

    

    Erica L. Mayer, MD, MPH

  1.50 program credits

• 

  RestartResume

  Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer

  RestartResume

  Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer

  MinuteCE®

  Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer

  1.50 program credits

  • 

    

    Erica L. Mayer, MD, MPH

  1.50 program credits

• 

  RestartResume

  The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer

  RestartResume

  The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer

  MinuteCE®

  The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer

  1.50 program credits

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 program credits

• 

  RestartResume

  The Evolving Treatment Landscape for MBC: Emerging Therapies

  RestartResume

  The Evolving Treatment Landscape for MBC: Emerging Therapies

  MinuteCE®

  The Evolving Treatment Landscape for MBC: Emerging Therapies

  1.50 program credits

  • 

    

    William J. Gradishar, MD

  1.50 program credits

• 

  RestartResume

  Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations

  RestartResume

  Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations

  MinuteCE®

  Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations

  1.50 program credits

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 program credits

• 

  RestartResume

  Emerging Treatment Approaches for EBC

  RestartResume

  Emerging Treatment Approaches for EBC

  MinuteCE®

  Emerging Treatment Approaches for EBC

  1.50 program credits

  • 

    

    William J. Gradishar, MD

  1.50 program credits